Skip to Highlights

Pursuant to a congressional request, GAO discussed the contractual relationship between the Department of Defense (DOD) and the BioPort Corporation for production of the anthrax vaccine, focusing on: (1) DOD's investment in BioPort's biologic facility and contracts to produce the vaccine; (2) BioPort's cash flow situation; and (3) proposals to improve the company's financial health.

Full Report